TrialRMD open2021

Randomised study of PF-06410293, an adalimumab (ADL) biosimilar, compared with reference ADL for the treatment of active rheumatoid arthritis: results from weeks 26-52, including a treatment switch from reference ADL to PF-06410293.

Roy M Fleischmann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.